Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of
Background: A person s genome is the collection of all their genes. A gene instructs individual cells to make proteins. Proteins are involved in all of our body s chemical processes. Genome sequencing allows researchers to find variations in genes. Some of these are normal and are not known to cause disease. Some varia
| Condition(s) | Human Immunodeficiency Virus, Castleman's Disease, Kaposi's Sarcoma, Viral-Associated Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Background: A person s genome is the collection of all their genes. A gene instructs individual cells to make proteins. Proteins are involved in all of our body s chemical processes. Genome sequencing allows researchers to find variations in genes. Some of these are normal and are not known to cause disease. Some variants are known to cause or affect diseases like cancer. Researchers want to study genetic variants in people with cancer who also have an immunologic disease like HIV. Objective: To study the biology of cancer in order to improve ways to prevent, detect, and treat it. Eligibility: Adults at least 18 years old with certain cancers and/or immunodeficiencies Design: Participants will be screened with medical history, physical exam, and lab tests. Participants will give samples of |
| Who can participate | * INCLUSION CRITERIA: Participants with one or more of the following: * HIV or other acquired immunodeficiency and cancer * Viral-associated cancer or cancer hypothesized to be caused by a virus * HIV-negative participants with cancer that commonly occurs in people with HIV --KSHV-associated malignancy or related diseases, such as Multicentric Castleman Disease (MCD) * A malignancy hypothesized to be caused by an endogenous retrovirus * Idiopathic Castleman disease Cancer diagnoses will be confirmed by the NCI Laboratory of Pathology (LP). A biopsy will be collected if sufficient archival tissue is not available. * Age \>=18 years. * ECOG performance status \<=2 (Karnofsky \>=60%) if biopsy to be performed is solely for the purposes of this protocol. Any ECOG performance status will be all |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | National Cancer Institute (NCI) |
| Locations | Bethesda, Maryland, United States |
| Start date | 2017-12-20 |
| NCT ID | NCT03300830 |
| Official listing | https://clinicaltrials.gov/study/NCT03300830 |